Grace Therapeutics
GRCE
9 hedge funds and large institutions have $704K invested in Grace Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.19% less ownership
Funds ownership: 3.57% → 3.38% (-0.19%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
93% less capital inflows, than outflows
Capital inflows: $2.7K | Capital outflows: $36.7K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
-$28K |
| 2 |
Renaissance Technologies
New York
|
-$4.36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$307 |
| 5 |
Tower Research Capital (TRC)
New York
|
-$61 |
GRCE Hedge Fund Activity: Q1 2017 in Review
9 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2017, worth a combined $704K — down 2.4% from $721K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of GRCE and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $28K sold.
- 9 institutional investors held Grace Therapeutics (GRCE) as of Q1 2017, down from 10 in Q4 2016.
- Funds reported $704K of Grace Therapeutics stock for Q1 2017, down 2.4% quarter-over-quarter.
- 1 fund opened new Grace Therapeutics positions in Q1 2017 and 2 closed out, a net change of -1 holder.
- The largest Grace Therapeutics seller in Q1 2017 was Virtu KCG Holdings, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2017.